Discontinued sales of Champix generics

Over 20 domestic pharmaceuticals

Withdrawal Notice, including Hutecs, C-tri, Danajen

Due to the loss of the patent dispute

Korea's top companies take action ahead

Anti-smoking drug Champix by Pfizer Korea

Pfizer's Champix (Varenicline) salt-changing patent disputes have resulted in the loss of more than 20 domestic pharmaceutical companies, which has resulted in the suspension and recovery of generic drugs.

 

According to the industry on the 24th, Hutecs Korea, C-tri, Danajen announced that they will be discontinued due to the result of a material patent evasion lawsuit by salt change of Champix This is because the patent court recently decided that “Champix generic anti-smoking drugs belong to products that differ from champix in the scope of the original material patent rights”.

 

The ruling halted sales and prescriptions of generic products in response to a preliminary order to prohibit patent infringement.

 

Increasingly, pharmaceutical companies are withdrawing from the market.

 

Hutecs has discontinued its sales of 0.5mg (11 tablets, PTP packaging) and 1mg (28 tablets, PTP packaging) sold by the company.

 

“It was due to the loss in the patent evasion litigation by changing the champix salt”, the company explained.

 

In addition, Hutecs requested to block the code so that it is not sold to wholesale trade or nursing homes and to treat as a normal return although not subject to compulsory recall but due to discontinuation.

 

C-tri has decided to discontinue the production of 0.5mg and 1mg of nicotine tablets.

 

C-tri announced that there will be no future reproduction after the stock runs out and excluded from contract sales items.

 

Danajen also stopped selling 0.5mg and 1mg of its Nicotine tablets on the 20th and began to collect all items.

 

Danajen decided to complete the collection by the 15th of next month.

 

In addition to coverage result of Dailypharm, the top domestic pharmaceutical companies that sell Champix generics have withdrawn from the market or are doing the same action.

 

JW Shinyak, Chong Kun Dang, Daewoong Pharmaceutical, and Il Dong Pharmaceutical Co., Ltd ceased production and marketing.

 

One of the pharmaceutical companies said, “We stopped prescribing and selling on the 23rd and will start returning products to pharmacies in the future, Other pharmaceutical companies also blocked both orders and sales”.

 

An official from the PR team in Korea, who had completed the recall, said, “After the solicitation of Solifenacin, we finished preparations for the suspension and recovery early.

 

Some pharmaceutical companies are quick to determine the profitability compared to marketing costs because they are unable to use the strategy to avoid salt changes”.

 

On the other hand, there were some companies still watching the situation.

 

A public relations executive at a mid-size pharmaceutical company said, “The sales department continues to sell, and we have not taken action yet”.